The University of Michigan, in partnership with pharmaceutical company AstraZeneca, is recruiting participants for phase 3 of a COVID-19 vaccine clinical trial.
The study is evaluating the vaccine AZD1222.
Hundreds of patients are needed to immediately participate in the trial. And across several states, AstraZeneca has a goal of including 30,000 individuals in the trial over a period of two years.
“The importance of a safe and effective vaccine against COVID-19 cannot be overstated," said Marschall Runge, M.D., Ph.D., Dean, U-M Medical School. "The AstraZeneca Phase III trial will bring answers as to the effectiveness of this vaccine. At the end of the day, this kind of rigorous clinical trial with the commitment of Michigan Medicine and other study sites to safety will be a key step in realizing a vaccine that will save lives when one is developed."
To take part in the trial, you must be 18 or older, in good or stable health (you may have an underlying medical condition and still take part, if your disease is stable), and you must not have had a previously confirmed diagnosis of COVID-19.
To sign up to volunteer, click here.
